Effect of telaprevir on the pharmacokinetics of sirolimus in liver transplant recipients.
Identifieur interne : 001057 ( Main/Exploration ); précédent : 001056; suivant : 001058Effect of telaprevir on the pharmacokinetics of sirolimus in liver transplant recipients.
Auteurs : Jacqueline G. O'Leary ; Gregory J. Mckenna ; Göran B. Klintmalm ; Gary L. DavisSource :
- Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society [ 1527-6473 ] ; 2013.
Descripteurs français
- KwdFr :
- Activation virale (MeSH), Antiviraux (effets indésirables), Antiviraux (usage thérapeutique), Association de médicaments (MeSH), Cirrhose du foie (chirurgie), Cirrhose du foie (diagnostic), Cirrhose du foie (virologie), Humains (MeSH), Hépatite C (diagnostic), Hépatite C (sang), Hépatite C (traitement médicamenteux), Immunosuppresseurs (usage thérapeutique), Interactions médicamenteuses (MeSH), Interféron alpha (usage thérapeutique), Oligopeptides (effets indésirables), Oligopeptides (usage thérapeutique), Polyéthylène glycols (usage thérapeutique), Protéines recombinantes (usage thérapeutique), Ribavirine (usage thérapeutique), Récidive (MeSH), Résultat thérapeutique (MeSH), Sirolimus (pharmacocinétique), Surveillance des médicaments (MeSH), Transplantation hépatique (effets indésirables), Transplantation hépatique (immunologie).
- MESH :
- chirurgie : Cirrhose du foie.
- diagnostic : Cirrhose du foie, Hépatite C.
- effets indésirables : Antiviraux, Oligopeptides, Transplantation hépatique.
- immunologie : Transplantation hépatique.
- pharmacocinétique : Sirolimus.
- sang : Hépatite C.
- traitement médicamenteux : Hépatite C.
- usage thérapeutique : Antiviraux, Immunosuppresseurs, Interféron alpha, Oligopeptides, Polyéthylène glycols, Protéines recombinantes, Ribavirine.
- virologie : Cirrhose du foie.
- Activation virale, Association de médicaments, Humains, Interactions médicamenteuses, Récidive, Résultat thérapeutique, Surveillance des médicaments.
English descriptors
- KwdEn :
- Antiviral Agents (adverse effects), Antiviral Agents (therapeutic use), Drug Interactions (MeSH), Drug Monitoring (MeSH), Drug Therapy, Combination (MeSH), Hepatitis C (blood), Hepatitis C (diagnosis), Hepatitis C (drug therapy), Humans (MeSH), Immunosuppressive Agents (therapeutic use), Interferon-alpha (therapeutic use), Liver Cirrhosis (diagnosis), Liver Cirrhosis (surgery), Liver Cirrhosis (virology), Liver Transplantation (adverse effects), Liver Transplantation (immunology), Oligopeptides (adverse effects), Oligopeptides (therapeutic use), Polyethylene Glycols (therapeutic use), Recombinant Proteins (therapeutic use), Recurrence (MeSH), Ribavirin (therapeutic use), Sirolimus (pharmacokinetics), Treatment Outcome (MeSH), Virus Activation (MeSH).
- MESH :
- chemical , adverse effects : Antiviral Agents, Oligopeptides.
- chemical , pharmacokinetics : Sirolimus.
- chemical , therapeutic use : Antiviral Agents, Immunosuppressive Agents, Interferon-alpha, Oligopeptides, Polyethylene Glycols, Recombinant Proteins, Ribavirin.
- adverse effects : Liver Transplantation.
- blood : Hepatitis C.
- diagnosis : Hepatitis C, Liver Cirrhosis.
- drug therapy : Hepatitis C.
- immunology : Liver Transplantation.
- surgery : Liver Cirrhosis.
- virology : Liver Cirrhosis.
- Drug Interactions, Drug Monitoring, Drug Therapy, Combination, Humans, Recurrence, Treatment Outcome, Virus Activation.
DOI: 10.1002/lt.23623
PubMed: 23408534
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Effect of telaprevir on the pharmacokinetics of sirolimus in liver transplant recipients.</title><author><name sortKey="O Leary, Jacqueline G" sort="O Leary, Jacqueline G" uniqKey="O Leary J" first="Jacqueline G" last="O'Leary">Jacqueline G. O'Leary</name></author><author><name sortKey="Mckenna, Gregory J" sort="Mckenna, Gregory J" uniqKey="Mckenna G" first="Gregory J" last="Mckenna">Gregory J. Mckenna</name></author><author><name sortKey="Klintmalm, Goran B" sort="Klintmalm, Goran B" uniqKey="Klintmalm G" first="Göran B" last="Klintmalm">Göran B. Klintmalm</name></author><author><name sortKey="Davis, Gary L" sort="Davis, Gary L" uniqKey="Davis G" first="Gary L" last="Davis">Gary L. Davis</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2013">2013</date><idno type="RBID">pubmed:23408534</idno><idno type="pmid">23408534</idno><idno type="doi">10.1002/lt.23623</idno><idno type="wicri:Area/Main/Corpus">001057</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001057</idno><idno type="wicri:Area/Main/Curation">001057</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">001057</idno><idno type="wicri:Area/Main/Exploration">001057</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Effect of telaprevir on the pharmacokinetics of sirolimus in liver transplant recipients.</title><author><name sortKey="O Leary, Jacqueline G" sort="O Leary, Jacqueline G" uniqKey="O Leary J" first="Jacqueline G" last="O'Leary">Jacqueline G. O'Leary</name></author><author><name sortKey="Mckenna, Gregory J" sort="Mckenna, Gregory J" uniqKey="Mckenna G" first="Gregory J" last="Mckenna">Gregory J. Mckenna</name></author><author><name sortKey="Klintmalm, Goran B" sort="Klintmalm, Goran B" uniqKey="Klintmalm G" first="Göran B" last="Klintmalm">Göran B. Klintmalm</name></author><author><name sortKey="Davis, Gary L" sort="Davis, Gary L" uniqKey="Davis G" first="Gary L" last="Davis">Gary L. Davis</name></author></analytic><series><title level="j">Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society</title><idno type="eISSN">1527-6473</idno><imprint><date when="2013" type="published">2013</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiviral Agents (adverse effects)</term><term>Antiviral Agents (therapeutic use)</term><term>Drug Interactions (MeSH)</term><term>Drug Monitoring (MeSH)</term><term>Drug Therapy, Combination (MeSH)</term><term>Hepatitis C (blood)</term><term>Hepatitis C (diagnosis)</term><term>Hepatitis C (drug therapy)</term><term>Humans (MeSH)</term><term>Immunosuppressive Agents (therapeutic use)</term><term>Interferon-alpha (therapeutic use)</term><term>Liver Cirrhosis (diagnosis)</term><term>Liver Cirrhosis (surgery)</term><term>Liver Cirrhosis (virology)</term><term>Liver Transplantation (adverse effects)</term><term>Liver Transplantation (immunology)</term><term>Oligopeptides (adverse effects)</term><term>Oligopeptides (therapeutic use)</term><term>Polyethylene Glycols (therapeutic use)</term><term>Recombinant Proteins (therapeutic use)</term><term>Recurrence (MeSH)</term><term>Ribavirin (therapeutic use)</term><term>Sirolimus (pharmacokinetics)</term><term>Treatment Outcome (MeSH)</term><term>Virus Activation (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Activation virale (MeSH)</term><term>Antiviraux (effets indésirables)</term><term>Antiviraux (usage thérapeutique)</term><term>Association de médicaments (MeSH)</term><term>Cirrhose du foie (chirurgie)</term><term>Cirrhose du foie (diagnostic)</term><term>Cirrhose du foie (virologie)</term><term>Humains (MeSH)</term><term>Hépatite C (diagnostic)</term><term>Hépatite C (sang)</term><term>Hépatite C (traitement médicamenteux)</term><term>Immunosuppresseurs (usage thérapeutique)</term><term>Interactions médicamenteuses (MeSH)</term><term>Interféron alpha (usage thérapeutique)</term><term>Oligopeptides (effets indésirables)</term><term>Oligopeptides (usage thérapeutique)</term><term>Polyéthylène glycols (usage thérapeutique)</term><term>Protéines recombinantes (usage thérapeutique)</term><term>Ribavirine (usage thérapeutique)</term><term>Récidive (MeSH)</term><term>Résultat thérapeutique (MeSH)</term><term>Sirolimus (pharmacocinétique)</term><term>Surveillance des médicaments (MeSH)</term><term>Transplantation hépatique (effets indésirables)</term><term>Transplantation hépatique (immunologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiviral Agents</term><term>Oligopeptides</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>Sirolimus</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term><term>Immunosuppressive Agents</term><term>Interferon-alpha</term><term>Oligopeptides</term><term>Polyethylene Glycols</term><term>Recombinant Proteins</term><term>Ribavirin</term></keywords><keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Liver Transplantation</term></keywords><keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Hepatitis C</term></keywords><keywords scheme="MESH" qualifier="chirurgie" xml:lang="fr"><term>Cirrhose du foie</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Hepatitis C</term><term>Liver Cirrhosis</term></keywords><keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Cirrhose du foie</term><term>Hépatite C</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Hepatitis C</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Antiviraux</term><term>Oligopeptides</term><term>Transplantation hépatique</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Transplantation hépatique</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Liver Transplantation</term></keywords><keywords scheme="MESH" qualifier="pharmacocinétique" xml:lang="fr"><term>Sirolimus</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Hépatite C</term></keywords><keywords scheme="MESH" qualifier="surgery" xml:lang="en"><term>Liver Cirrhosis</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Hépatite C</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antiviraux</term><term>Immunosuppresseurs</term><term>Interféron alpha</term><term>Oligopeptides</term><term>Polyéthylène glycols</term><term>Protéines recombinantes</term><term>Ribavirine</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Cirrhose du foie</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Liver Cirrhosis</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Drug Interactions</term><term>Drug Monitoring</term><term>Drug Therapy, Combination</term><term>Humans</term><term>Recurrence</term><term>Treatment Outcome</term><term>Virus Activation</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Activation virale</term><term>Association de médicaments</term><term>Humains</term><term>Interactions médicamenteuses</term><term>Récidive</term><term>Résultat thérapeutique</term><term>Surveillance des médicaments</term></keywords></textClass></profileDesc></teiHeader></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23408534</PMID><DateCompleted><Year>2013</Year><Month>09</Month><Day>13</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1527-6473</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>4</Issue><PubDate><Year>2013</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society</Title><ISOAbbreviation>Liver Transpl</ISOAbbreviation></Journal><ArticleTitle>Effect of telaprevir on the pharmacokinetics of sirolimus in liver transplant recipients.</ArticleTitle><Pagination><MedlinePgn>463-5</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/lt.23623</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>O'Leary</LastName><ForeName>Jacqueline G</ForeName><Initials>JG</Initials></Author><Author ValidYN="Y"><LastName>McKenna</LastName><ForeName>Gregory J</ForeName><Initials>GJ</Initials></Author><Author ValidYN="Y"><LastName>Klintmalm</LastName><ForeName>Göran B</ForeName><Initials>GB</Initials></Author><Author ValidYN="Y"><LastName>Davis</LastName><ForeName>Gary L</ForeName><Initials>GL</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Liver Transpl</MedlineTA><NlmUniqueID>100909185</NlmUniqueID><ISSNLinking>1527-6465</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016898">Interferon-alpha</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009842">Oligopeptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>3WJQ0SDW1A</RegistryNumber><NameOfSubstance UI="D011092">Polyethylene Glycols</NameOfSubstance></Chemical><Chemical><RegistryNumber>49717AWG6K</RegistryNumber><NameOfSubstance UI="D012254">Ribavirin</NameOfSubstance></Chemical><Chemical><RegistryNumber>655M5O3W0U</RegistryNumber><NameOfSubstance UI="C486464">telaprevir</NameOfSubstance></Chemical><Chemical><RegistryNumber>Q46947FE7K</RegistryNumber><NameOfSubstance UI="C100416">peginterferon alfa-2a</NameOfSubstance></Chemical><Chemical><RegistryNumber>W36ZG6FT64</RegistryNumber><NameOfSubstance UI="D020123">Sirolimus</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004347" MajorTopicYN="N">Drug Interactions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016903" MajorTopicYN="N">Drug Monitoring</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006526" MajorTopicYN="N">Hepatitis C</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016898" MajorTopicYN="N">Interferon-alpha</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008103" MajorTopicYN="N">Liver Cirrhosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016031" MajorTopicYN="Y">Liver Transplantation</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009842" MajorTopicYN="N">Oligopeptides</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011092" MajorTopicYN="N">Polyethylene Glycols</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012254" MajorTopicYN="N">Ribavirin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020123" MajorTopicYN="N">Sirolimus</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="Y">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014775" MajorTopicYN="N">Virus Activation</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>01</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>01</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>2</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>2</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>9</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23408534</ArticleId><ArticleId IdType="doi">10.1002/lt.23623</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list></list><tree><noCountry><name sortKey="Davis, Gary L" sort="Davis, Gary L" uniqKey="Davis G" first="Gary L" last="Davis">Gary L. Davis</name><name sortKey="Klintmalm, Goran B" sort="Klintmalm, Goran B" uniqKey="Klintmalm G" first="Göran B" last="Klintmalm">Göran B. Klintmalm</name><name sortKey="Mckenna, Gregory J" sort="Mckenna, Gregory J" uniqKey="Mckenna G" first="Gregory J" last="Mckenna">Gregory J. Mckenna</name><name sortKey="O Leary, Jacqueline G" sort="O Leary, Jacqueline G" uniqKey="O Leary J" first="Jacqueline G" last="O'Leary">Jacqueline G. O'Leary</name></noCountry></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Bois/explor/RapamycinFungusV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001057 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001057 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Bois
|area= RapamycinFungusV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:23408534
|texte= Effect of telaprevir on the pharmacokinetics of sirolimus in liver transplant recipients.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:23408534" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a RapamycinFungusV1
| This area was generated with Dilib version V0.6.38. |  |